despit
outstand
success
control
diseas
provid
improv
sanit
immun
antimicrobi
therapi
infecti
diseas
continu
common
signific
medic
problem
infecti
diseas
take
mani
manifest
common
diseas
mankind
common
cold
infecti
diseas
fearsom
modern
diseas
acquir
immun
defici
syndrom
aid
chronic
neurolog
diseas
previous
thought
degen
proven
infecti
well
infecti
diseas
caus
infect
agent
pathogen
bacteria
virus
fungi
parasit
infecti
diseas
pass
person
person
howev
transmit
via
anim
other
acquir
ingest
contamin
food
water
exposur
environ
microb
especi
virus
unstabl
evolv
rapidli
past
year
new
organ
identifi
worldwid
emerg
new
newli
recogn
pathogen
virus
caus
novel
viral
hepat
sever
acut
respiratori
syndrom
sar
ebola
highli
pathogen
modifi
strain
influenza
viru
alter
entir
insight
public
health
also
increas
awar
potenti
novel
establish
infect
anim
cross
speci
barrier
affect
man
avian
flu
swine
flu
mani
old
infecti
diseas
tuberculosi
becom
renasc
due
relax
control
measur
result
satisfact
increas
resist
antimicrobi
agent
social
factor
includ
increas
travel
social
displac
poverti
long
establish
infect
expand
previous
unaffect
region
exampl
west
nile
viru
north
america
threat
bioterror
rais
spectra
new
outbreak
highli
infecti
deadli
diseas
smallpox
anthrax
prion
diseas
variant
diseas
vcjd
plagu
evid
global
climat
chang
might
contribut
spread
infecti
diseas
unless
control
effect
emerg
infecti
diseas
take
heavi
toll
human
life
regardless
age
gender
lifestyl
ethnic
background
socioeconom
statu
infecti
diseas
may
caus
suffer
death
also
impos
enorm
financi
burden
societi
henc
effort
continu
prevent
care
treatment
infecti
diseas
convent
novel
formul
technolog
variou
drug
describ
elsewher
book
also
applic
deliveri
chemotherapeut
agent
use
treat
infecti
diseas
via
oral
parenter
transderm
transmucos
rout
howev
focu
chapter
vaccin
use
prevent
andor
therapi
infecti
diseas
requir
quit
differ
formul
approach
compar
use
deliv
convent
drug
adjuv
defin
molecul
compound
macromolecular
complex
boost
potenc
longev
specif
immun
respons
antigen
caus
minim
toxic
long
last
immun
effect
adjuv
act
divers
seri
pathway
may
involv
chang
properti
antigen
provid
slow
releas
antigen
depot
target
innat
immun
pathway
select
activ
specif
pathway
immun
regard
mechan
action
adjuv
classifi
two
group
follow
immunostimul
act
directli
immun
system
increas
respons
antigen
stimul
immun
respons
exampl
includ
tlr
tolllik
receptor
ligand
cytokin
gmcsf
saponin
bacteri
exotoxin
ct
cholera
toxin
lt
heat
labil
enterotoxin
escherichia
coli
vehicl
deliveri
system
present
vaccin
antigen
immun
system
optim
manner
includ
control
releas
depot
deliveri
system
increas
specif
immun
respons
antigen
also
serv
deliv
immunostimul
exampl
includ
follow
miner
salt
aluminum
emuls
virosom
liposom
biodegrad
polymer
microparticl
immun
stimul
complex
iscom
current
adjuv
deliveri
system
licens
human
use
includ
alum
oilinwat
emuls
contain
nonion
surfact
squalen
incorpor
influenza
vaccin
novarti
oilinwat
emuls
contain
squalen
incorpor
pandem
influenza
vaccin
gsk
monophosphoryl
lipid
alum
incorpor
human
papilloma
viru
vaccin
hepat
b
viru
hbv
vaccin
gsk
viruslik
particl
vlp
selfassembl
particl
compos
one
viral
protein
immunopotenti
reconstitut
influenza
virosom
iriv
hepat
viru
particl
adsorb
surfac
iriv
v
influenza
berna
crucel
compani
cholera
toxin
safeti
adjuv
still
remain
import
issu
mani
adjuv
report
show
undesir
effect
preserv
phenol
benzethonium
chlorid
also
ad
formul
prevent
bacteri
fungal
growth
vaccin
storag
particularli
use
open
multidos
vial
thiomers
also
known
thimeros
mercurothiol
sodium
approxim
mercuri
weight
one
commonli
use
preserv
vaccin
formul
also
use
vaccin
product
inactiv
certain
organ
toxin
maintain
steril
product
line
recent
concern
safeti
compound
due
mercuri
content
safeti
concern
led
initi
countri
elimin
reduc
replac
thiomers
vaccin
singl
dose
multidos
present
howev
global
advisori
committe
vaccin
safeti
continu
recommend
use
vaccin
contain
thiomers
global
immun
programm
benefit
use
product
far
outweigh
theoret
risk
toxic
stabil
solubil
polyoxyethylen
sorbitan
monool
toctylphenoxypolyethoxyethanol
octoxynol
ad
vaccin
formul
improv
formul
characterist
dispers
sugar
sucros
lactos
amino
acid
glycin
monosodium
salt
glutam
acid
protein
human
serum
albumin
gelatin
also
ad
stabil
sometim
ad
help
protect
vaccin
effect
advers
condit
encount
freez
dri
process
vaccin
freez
dri
vaccin
prepar
store
within
specif
temperatur
rang
maintain
potenc
cold
chain
system
often
mean
store
transport
vaccin
potent
state
manufactur
person
immun
fig
approach
import
sinc
vaccin
lose
potenc
time
expos
heat
andor
frozen
howev
innov
technolog
base
vaccin
cold
chain
system
may
costli
due
requir
significantli
space
transport
storag
therefor
develop
thermost
vaccin
formul
becom
import
consider
transcutaneuo
immun
tci
novel
vaccin
rout
involv
topic
applic
vaccin
antigen
onto
skin
surfac
shown
skin
effect
immun
system
physic
barrier
imperm
previous
thought
henc
becam
attract
rout
noninvas
deliveri
vaccin
studi
sever
anim
speci
clinic
trial
human
establish
proof
principl
mucos
immun
focus
oral
nasal
aerosol
vaccin
vaccin
induc
protect
mucos
immun
attract
sinc
infecti
agent
come
contact
host
mucos
surfac
mucos
deliveri
vaccin
allow
concert
action
diseas
caus
pathogen
either
invad
caus
diseas
mucos
surfac
gener
approach
combin
system
respons
local
mucos
immun
respons
induc
specif
protect
distant
mucos
site
jet
injector
needl
free
devic
deliv
vaccin
nozzl
orific
via
high
pressur
high
speed
narrow
stream
penetr
skin
gener
improv
equival
immun
respons
compar
needl
syring
vaccin
deliv
intraderm
subcutan
intramuscular
tissu
depend
mechan
properti
fluid
stream
multidos
jet
injector
use
wide
billion
immun
given
devic
howev
concern
transmiss
blood
born
diseas
via
devic
led
withdraw
new
gener
multidos
jet
injector
dispos
cap
nozzl
develop
attempt
overcom
risk
howev
found
adequ
safe
older
injector
use
nozzl
consecut
patient
supersed
new
gener
dispos
cartridg
jet
injector
dcji
current
use
usa
needl
free
immun
adult
pediatr
popul
sever
vaccin
fig
devic
current
use
rel
expens
suit
use
develop
countri
henc
develop
smaller
lighter
cheaper
design
could
applic
routin
campaign
immun
requir
travel
diarrhea
td
vaccin
patch
intercel
report
enter
clinic
phase
iii
develop
td
vaccin
system
consist
selfadhes
patch
contain
vaccin
antigen
singl
use
devic
use
prepar
skin
site
patch
administr
skin
prepar
system
partial
disrupt
stratum
corneum
skin
dri
patch
contain
antigen
stabil
excipi
formul
deliv
antigen
skin
activ
langerhan
cell
take
antigen
deliv
drain
lymph
node
approv
first
vaccin
deliv
patch
prevent
td
caus
enterotoxigen
e
coli
note
ad
proof
develop
product
halt
follow
failur
phase
iii
similarli
patch
contain
trival
inactiv
influenza
vaccin
tiv
develop
dri
stabil
formul
transcutan
deliveri
dri
tiv
patch
describ
major
advanc
needl
free
influenza
vaccin
due
effect
vaccin
deliveri
superior
thermost
characterist
nasal
rout
offer
sever
benefit
administr
vaccin
highli
vascular
mucou
membran
low
enzymat
degrad
compar
oral
vaccin
greater
accept
patient
nasal
vaccin
howev
overcom
sever
limit
includ
mucociliari
clearanc
ineffici
uptak
solubl
antigen
therefor
nasal
vaccin
requir
potent
adjuv
deliveri
system
enhanc
immunogen
protect
antigen
among
variou
bioadhes
polym
studi
nasal
vaccin
deliveri
chitosan
shown
exhibit
advantag
vaccin
carrier
due
immun
stimul
activ
bioadhes
properti
enhanc
cellular
uptak
permeat
antigen
protect
well
well
toler
human
medimmun
llc
usa
first
fda
approv
needl
free
influenza
vaccin
made
weaken
live
viru
live
attenu
influenza
vaccin
laiv
given
gentl
mist
quick
spray
nostril
engin
caus
diseas
replic
effici
cooler
temperatur
nasopharynx
warmer
temperatur
lower
respiratori
tract
influenza
monoval
vaccin
live
medimmun
llc
usa
second
nasal
vaccin
approv
recent
fda
pandem
influenza
neither
vaccin
formul
contain
adjuv
measl
aerosol
project
establish
collabor
us
center
diseas
control
prevent
american
red
cross
purpos
conduct
necessari
studi
achiev
licensur
product
devic
vaccin
administ
rout
long
recogn
new
deliveri
system
may
facilit
measl
immun
effort
especi
mass
campaign
approach
may
facilit
longterm
sustain
measl
mortal
reduct
measl
elimin
goal
studi
undertaken
least
three
devic
aerosol
administr
reconstitut
vaccin
feasibl
time
frame
dri
powder
devic
vaccin
deliveri
system
gener
particul
system
eg
emuls
polymer
micronanoparticl
iscom
liposom
mainli
function
target
associ
antigen
antigen
present
cell
apc
includ
macrophag
dendrit
cell
facilit
immun
respons
hold
antigen
surfac
present
lymphocyt
significantli
enhanc
immun
respons
report
encapsul
adsorpt
antigen
onto
particl
polyanhydrid
polyorthoest
hyaluron
acid
poli
lacticcoglycol
acid
plga
commonli
investig
polym
prepar
particul
system
prepar
method
employ
obtain
system
report
import
paramet
stabil
antigen
mani
case
organ
solvent
high
temperatur
need
prepar
particl
may
result
degrad
denatur
antigen
process
load
use
algin
chitosan
offer
advantag
polym
avoid
use
organ
solvent
requir
mild
condit
prepar
particul
system
particl
size
smaller
report
significantli
improv
immun
respons
howev
varieti
system
within
wide
rang
particl
size
nm
investig
antigen
deliveri
investig
show
clear
confirm
decreas
particl
size
deliveri
system
improv
immun
respons
also
still
inconsist
literatur
differenti
uptak
nanoparticl
antigen
present
cell
apc
chang
accord
particl
antigen
properti
well
applic
rout
current
vaccin
product
avail
market
base
polymer
particul
system
oral
immun
vaccin
intestin
infecti
diseas
extens
explor
sever
decad
despit
immunolog
econom
rational
behind
oral
immun
mucos
vaccin
avail
prevent
mucos
infect
due
limit
absorpt
intestin
tract
sensit
degrad
oral
polio
vaccin
opv
contain
live
weaken
polioviru
whorecommend
vaccin
polio
erad
howev
risk
rare
seriou
condit
call
vaccineassoci
paralyt
poliomyel
use
oral
polio
vaccin
usa
discontinu
current
two
oral
vaccin
approv
fda
typhoid
vaccin
live
oral
enter
coat
tablet
berna
ltd
rotaviru
vaccin
live
oral
readytous
liquid
dose
msd
lyophil
vaccin
reconstitut
liquid
diluent
prefil
oral
applic
gsk
recent
new
liveattenu
bacteri
viral
edibl
plant
deriv
vaccin
introduc
oral
vaccin
plant
use
recombin
biofactori
express
number
vaccin
plant
deriv
vaccin
antigen
found
safe
induc
suffici
high
immun
respons
human
henc
transgen
plant
includ
edibl
plant
part
suggest
excel
altern
product
vaccin
econom
scaleup
cultiv
edibl
encapsul
protect
antigen
mucos
gut
system
allow
uptak
furthermor
oral
plant
base
vaccin
report
stabl
storag
ambient
temperatur
therebi
elimin
need
cold
chain
addit
requir
syring
needl
train
personnel
administr
featur
also
favor
use
vaccin
larg
scale
immun
programm
particularli
develop
countri
resourc
provid
cold
chain
equip
personnel
need
inject
limit
initi
transgen
fruit
veget
express
antigen
viru
bacteria
edibl
vaccin
intend
eaten
raw
without
process
evok
protect
immun
respons
particular
diseas
howev
recent
approach
edibl
vaccin
replac
plantderiv
vaccin
antigen
approach
result
antigen
pure
form
standard
concentr
gener
plant
high
food
valu
chosen
express
system
appl
banana
tomato
guava
fruit
peanut
corn
soybean
chickpea
seed
cabbag
lettuc
potato
spinach
veget
recent
rice
base
mucos
vaccin
express
ctb
mucoric
ctb
report
new
possibl
form
oral
cholera
vaccin
transgen
rice
shown
stabl
harsh
environ
gastrointestin
tract
also
elimin
need
syringeneedl
administr
well
cold
chain
storag
process
provid
physicochem
stabil
howev
point
highli
sophist
close
soilless
farm
facil
artifici
sunlight
would
requir
technic
advanc
rice
base
transgen
vaccin
system
vaccin
definit
prophylact
recent
year
therapeut
vaccin
develop
chronic
viral
infect
caus
hepat
b
viru
human
papilloma
viru
hpv
herp
simplex
viru
hiv
therapeut
vaccin
intend
treat
persist
recurr
chronic
infect
drug
intervent
either
ineffect
suboptim
intracellular
pathogen
establish
mechan
escap
immun
system
unlik
tradit
vaccin
administ
healthi
individu
prevent
infect
therapeut
vaccin
design
stimul
immun
defenc
patient
popul
infectedcolon
pathogen
even
develop
diseas
therapeut
vaccin
propos
satisfactori
replac
adjunct
exist
therapi
alway
risk
benefit
associ
use
vaccin
side
effect
vaccin
often
report
howev
consid
fact
person
risk
infect
report
confirm
safeti
vaccin
immun
consid
first
line
defens
infecti
diseas
respons
challeng
global
immun
unicef
develop
global
immun
vision
strategi
giv
cover
period
strategi
aim
assist
countri
immun
peopl
infant
senior
greater
rang
vaccin
introduc
rang
newli
avail
vaccin
technolog
fulfil
main
mission
world
peopl
risk
protect
vaccineprevent
diseas
formul
also
mission
immun
peopl
ie
develop
safe
potent
vaccin
deliveri
system
stabl
temperatur
selfadministr
suitabl
packag
storag
transport
afford
